Search
for
Sort by
Research 31–60 of 1000+
- New Nonsteroidal Molecules as Blockers of the Steroidogenic Pathway
- Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy
- Search for New antineoplastic agents based on structural modifications of steroidal 5α-reductase, 17β-hydroxysteroid dehydrogenase, and 17α-hydroxylase/17,20-lyase inhibitors
- Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- Abietic Acid from Resina Pini of Pinus Species as a Testosterone 5.ALPHA.-Reductase Inhibitor
- Effect of C-ring modifications in benzo[c]quinolizin-3-ones, new selective inhibitors of human 5α-reductase 1
- Synthesis and biological evaluation of esters of 16-formyl-17-methoxy-dehydroepiandrosterone derivatives as inhibitors of 5α-reductase type 2
- 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
- Rational Design of a Topical Androgen Receptor Antagonist for the Suppression of Sebum Production with Properties Suitable for Follicular Delivery
- Psoriatic onychopachydermoperiostitis: improvement with etanercept
- Hormone Blocking Anticancer Drugs
- Treatment of androgen excess in females: Yesterday, today and tomorrow
- Chapter 23. Therapeutic Control of Androgen Action
- Steroid 5α-reductase inhibition by polymethoxyflavones
- Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
- Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles.
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Celiac Disease: Beyond Diet and Food Awareness
- Topical Finasteride Therapy in Hirsutism
- Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides as 5.alpha.-Reductase Inhibitors and Antiandrogens
- Pharmacophore and Atom Based 3D QSAR Studies on the Novel 5-Alpha-Reductase Inhibitors
- Synthesis and Structure–Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata